Sirna Therapeutics Commences Phase I Clinical Trial for Age-Related Macular Degeneration at Cleveland Clinic
... most advanced RNAi therapeutic, Sirna-027, for patients with age-related macular degeneration (AMD), with the ... Age-related macular degeneration is the leading cause of visual ...
NOVA | scienceNOW | The RNAi Cure | PBS
In this feature, learn about possible applications for RNAi therapy. ... debilitating eye disease called macular degeneration. Biotech firms had ... engineered RNAi molecules to shut down various RSV genes. Like the treatment for macular degeneration, these ...
Huntington's Disease Advocacy Center - Research Updates
This portal provides information about the latest research. ... we suggest you visit the HD Lighthouse. RNAi update - macular degeneration clinical trial going well. ... Here we go - RNAi clinical trials start for macular degeneration. Inhibiting the ...
RNAi
RNAi: Sirna Therapeutics is a leading developer of therapeutics based on RNA interference (RNAi) technology. ... RNAi (RNA Interference) technology is offering promising treatments across a wide array of diseases, including Macular Degeneration ... cancer research.) RNAi is the process of using ...
Globeinvestor.com: Sirna Therapeutics Commences Phase I Clinical Trial for Age-Related Macular Degeneration at ...
Enter Symbols (Lookup): News from PR Newswire. Sirna Therapeutics Commences Phase I Clinical Trial for Age-Related Macular Degeneration at Cleveland Clinic. 07:30 EST Tuesday, November 23, 2004. BOULDER, Colo., Nov. ... most advanced RNAi therapeutic, Sirna-027, for patients with age-related macular degeneration (AMD), with the ... Age-related macular degeneration is the leading cause of visual ...
News Release
... First IND Filing Applies Novel RNAi Therapy to the Treatment of Age-Related Macular Degeneration ... in patients with age-related macular degeneration (AMD), the leading cause of ...
Khera 1
... RNA interference (RNAi) has revolutionized not only the basic field of molecular biology, but also ... underway for an RNAi-based treatment for macular degeneration, recent studies have ...
BioSpace News: Macular degeneration
News Resources Jobs Companies Diseases Events Experts Glossary ... Data Presented On RNAi Therapeutics For Age-Related Macular Degeneration; Preclinical Data Reported ... diseases such as age-related macular degeneration (AMD). Experiments in an animal ...
RNAi Enters the Clinic for Macular Degeneration
... RNAi Enters the Clinic for Macular Degeneration. (A#2004900231) ... siRNA entered Phase I trials in age-related macular degeneration (AMD). Sirna followed suit in late November with ...
Sirna to Present Progress in Its Macular Degeneration Program at the Nucleic Acid World Summit
... Nasdaq: RNAI) will present new data on the company's age-related macular degeneration (AMD) program at ... Age-related macular degeneration (AMD) is a leading cause of blindness in ...
News Release
News Release. 11/23/2004. Sirna Therapeutics Commences Phase I Clinical Trial for Age-Related Macular Degeneration at Cleveland Clinic. First Trial to Evaluate a Chemically Optimized siRNA in Patients. BOULDER, Colo., Nov. ... most advanced RNAi therapeutic, Sirna-027, for patients with age-related macular degeneration (AMD), with the ... Age-related macular degeneration is the leading cause of visual ...
News & Events
... Nasdaq: RNAI) will present new data on the company's age-related macular degeneration (AMD) program at ... Age-related macular degeneration (AMD) is a leading cause of blindness in ...
Blind World - Requested Article
Macular Degeneration. Two firms stake their claims to RNAi, an emerging biotech category. March 8, 2004. By Matt Branaugh, Camera Business Writer, The Daily Camera. ... believes its best first target is macular degeneration. The disease, found mostly among ...
Sirna Therapeutics, Inc. :: Sirna Therapeutics Commences Phase I Clinical Trial for Age-Related Macular Degeneration...
... most advanced RNAi therapeutic, Sirna-027, for patients with age-related macular degeneration (AMD), with the ... Age-related macular degeneration is the leading cause of visual ...
RNA Interference
RNA Interference: Sirna Therapeutics is a leading developer of therapeutics based on RNA interference (RNAi) technology. ... RNAi Interference (RNAi) technology is offering promising treatments across a wide array of diseases, including Macular Degeneration ... cancer research.) RNAi is the process of using ...
Macular Degeneration Update
Macular Degeneration Update. (10/7/05)- Genentech's Lucentis, which is a drug that has shown promise in reversing the effects of age related macular degeneration is a derivative of its drug Avastin. ... for an RNAi-based drug in on ongoing phase I trial for age-related macular degeneration (AMD). The objective ...
Sirna Therapeutics' First IND Filing Applies Novel RNAi Therapy to the Treatment of Age-Related Macular Degeneration
... First IND Filing Applies Novel RNAi Therapy to the Treatment of Age-Related Macular Degeneration ... in patients with age-related macular degeneration (AMD), the leading cause of ...
Biomedical Smart Macular Degeneration - Market Research
Research on Biomedical Smart Macular Degeneration. Access thousands of top-notch market reports - analysis, statistics, forecasts, and industry data at MarketResearch.com.
Sirna Therapeutics Phase 1 Drug Candidate Highlighted on PBS NOVA scienceNow: Financial News - Yahoo! Finance
... for age-related macular degeneration (AMD) was highlighted on ... developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD ...
A crucial test
... in Boulder, Colorado, which is also using RNAi to treat macular degeneration. Over the next year, a ... plans to test its RNAi therapy against macular degeneration. Alnylam also hopes ...
NOTE: Please contact us right away if you'd like to make any changes to your listing.
Home | Index
|
